Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma

June 7, 2022|Comments Off on Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma

Malinga NZ, Siwele SC, Steel HC, Kwofie LLI, Meyer PWA, Smit T, et al. Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma. Transl Oncol. 2022;19:101384.


Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South Africa

June 7, 2022|Comments Off on Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South Africa

Majam M, Msolomba V, Venter F, Scott LE, Kahamba T, Stevens WS, et al. Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South Africa. Diagnostics (Basel). 2022;12(2).


Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention

June 7, 2022|Comments Off on Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention

Mahomed S, Garrett N, Capparelli EV, Osman F, Harkoo I, Yende-Zuma N, et al. Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention. J Infect Dis. 2022.


Molecular characterisation and detection of macrolide and fluoroquinolone resistance determinants in Mycoplasma genitalium in South Africa, 2015-2018

June 7, 2022|Comments Off on Molecular characterisation and detection of macrolide and fluoroquinolone resistance determinants in Mycoplasma genitalium in South Africa, 2015-2018

Mahlangu MP, Müller EE, Da Costa Dias B, Venter JM, Kularatne RS. Molecular characterisation and detection of macrolide and fluoroquinolone resistance determinants in Mycoplasma genitalium in South Africa, 2015-2018. Sex Transm Dis. 2022.


Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study

June 7, 2022|Comments Off on Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study

Mahlangu J, Abdul Karim F, Stasyshyn O, Korczowski B, Salazar B, Lucas S, et al. Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study. Res Pract Thromb Haemost. 2022;6(2):e12665.